Methods A Phase III, randomized, double-blind, parallel-group trial (NCT01316380)
evaluated the efficacy and safety of once-daily tiotropium Respimat® 5 μg or 2.5 μg versus …

Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the
management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA …

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled
corticosteroids (ICS) plus one or more controller therapies in adolescents with severe …

There remains an unmet need for effective, well-tolerated therapeutic options in paediatric
patients with not fully controlled asthma, for whom safety is of paramount importance. Data …

Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by
blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide …

Background Few studies have assessed the safety and efficacy of potential asthma
medications in children younger than 5 years. We descriptively assessed the safety and …

Tiotropium is a long-acting inhaled antimuscarinic bronchodilator that has recently received
marketing authorization for the indication of asthma with dose delivery via the Respimat® …

Asthma is a chronic respiratory disease characterized by reversible airway obstruction that is
secondary to an allergic inflammation and excessive smooth muscle contraction …

Background Tiotropium has activity as an asthma controller. However, predictors of a
positive response to tiotropium have not been described. Objective We sought to describe …

Background Tiotropium, a long-acting anticholinergic bronchodilator, has demonstrated
efficacy and safety as add-on therapy to inhaled corticosteroids (ICS), with or without other …